Thomas N. Seyfried, PhD, Boston College

Thomas N. Seyfried, PhD
Thomas N. Seyfried, PhD

The Seyfried laboratory focuses on mechanisms by which metabolic therapy manages chronic diseases such as epilepsy, neurodegenerative lipid storage diseases, and cancer. The metabolic therapies include caloric restriction, fasting, and ketogenic diets. Their approach is based on the idea that compensatory metabolic pathways are capable of modifying the pathogenesis of complex diseases. Global shifts in metabolic environment can neutralize molecular pathology. In the case of cancer, these therapies target and kill tumor cells while enhancing the physiological health of normal cells. The neurochemical and genetic mechanisms of these phenomena are under investigation in novel animal models and include the processes of inflammation, cellular physiology, angiogenesis, and lipid biochemistry.

The Investigator's Annexe Part of The Investigator's Annexe program.

Products

References

  1. Poff AM, Ari C, Seyfried TN, D'Agostino DP. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One. 2013 Jun 5;8(6):e65522.
  2. Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18(1-2):43-73.
  3. Strelko CL, Lu W, Dufort FJ, Seyfried TN, Chiles TC, Rabinowitz JD, Roberts MF. Itaconic acid is a mammalian metabolite induced during macrophage activation. J Am Chem Soc. 2011 Oct 19;133(41):16386-9.
  4. Huysentruyt LC, Akgoc Z, Seyfried TN. Hypothesis: are neoplastic macrophages/microglia present in glioblastoma multiforme?ASN Neuro. 2011 Sep 22;3(4).
  5. Huysentruyt LC, Seyfried TN. Perspectives on the mesenchymal origin of metastatic cancer. Cancer Metastasis Rev. 2010 Dec;29(4):695-707.
  6. Shelton LM, Huysentruyt LC, Mukherjee P, Seyfried TN. Calorie restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. ASN Neuro. 2010 Jul 23;2(3):e00038.
  7. Shelton LM, Huysentruyt LC, Seyfried TN. Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. Int J Cancer. 2010 Nov 15;127(10):2478-85.
  8. Shelton LM, Mukherjee P, Huysentruyt LC, Urits I, Rosenberg JA, Seyfried TN. A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. J Neurooncol. 2010 Sep;99(2):165-76.
  9. Huysentruyt LC, Shelton LM, Seyfried TN. Influence of methotrexate and cisplatin on tumor progression and survival in the VM mouse model of systemic metastatic cancer. Int J Cancer. 2010 Jan 1;126(1):65-72.
  10. Huysentruyt LC, Mukherjee P, Banerjee D, Shelton LM, Seyfried TN. Metastatic cancer cells with macrophage properties: evidence from a new murine tumor model. Int J Cancer. 2008 Jul 1;123(1):73-84.